In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...

On today’s CT BUZZ, Host Natasha Lubczenko sat down with Dr. Zach Korwin, owner of Sleep Stratford, to discuss an innovative ...

Inspire Medical Systems (NYSE:INSP – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at KeyCorp in a research note issued to investors on Friday,Benzinga ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $231.12, a high ...

KeyBanc Capital Markets adjusted its price target on Inspire Medical Systems (NYSE:INSP) shares, lowering it to $234 from $236, while maintaining an Overweight rating on the stock. The revision ...

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Inspire Medical Systems (INSP – Research Report), with a ...

Stifel analysts adjusted their outlook on Inspire Medical Systems (NYSE:INSP), reducing the price target to $190 from the previous $200 while maintaining a Hold rating on the stock. The revision ...

Medicare covers sleep tests for certain conditions such as sleep apnea, narcolepsy, or parasomnia, but limitations may apply.

Stifel Nicolaus analyst Jonathan Block maintained a Hold rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price ...

Bedtime should be relaxing. But if allergies, asthma, sleep apnea, or gastroesophageal reflux (GERD) are keeping you awake, it can feel like a nightly stress test. We’ve got good news.